PHARMACOKINETIC STUDY OF BRAMITOB ADMINISTERED FOR INHALATION BY PARI eFLOW RAPID ELECTRONIC NEBULIZER VS PARI LC PLUS NEBULIZER COUPLED WITH THE PARI TURBO BOY N COMPRESSOR IN CYSTIC FIBROSIS PATIENTS INFECTED WITH PSEUDOMONAS AERUGINOSA.

Trial Profile

PHARMACOKINETIC STUDY OF BRAMITOB ADMINISTERED FOR INHALATION BY PARI eFLOW RAPID ELECTRONIC NEBULIZER VS PARI LC PLUS NEBULIZER COUPLED WITH THE PARI TURBO BOY N COMPRESSOR IN CYSTIC FIBROSIS PATIENTS INFECTED WITH PSEUDOMONAS AERUGINOSA.

Completed
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2012

At a glance

  • Drugs Tobramycin (Primary)
  • Indications Pseudomonal infections
  • Focus Pharmacokinetics
  • Most Recent Events

    • 16 Nov 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 16 Nov 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Feb 2011 Additional lead trial investigators identified and additional locations identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top